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Mast Cells in Human Stenotic Aortic Valves Are Associated
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Abstract—Aortic valve stenosis (AS) is characterized by extensive calcification of the aortic valve
leaflets and infiltration of inflammatory cells. Activated mast cells (MCs) may participate in the
induction of fibrosis and calcification with ensuing valve stiffening. We sought to investigate wh-
ether the number of MCs within stenotic aortic valves is associated with the severity of AS. We
studied 43 patients (19 men, 24 women) with dominant AS (age, 64.2±5.9 years; mean transvalvular
pressure gradient, 62.11±24.47 mmHg) without atherosclerotic vascular disease, undergoing elective
aortic valve replacement. MCs were detected in the excised valves by immunostaining. Aortic valves
from five healthy subjects obtained on autopsy served as negative controls. The number of tryptase- and
chymase-positive MCs was increased in AS valves compared with the control valves (6.9 [2.3–18.9]/
mm2 vs. 0.7 [0–2.2]/mm2, P00.0001 and 3.2 [2.1–9.4]/mm2 vs. 0.3 [0–1.9]/mm2, P00.002,
respectively). MCs that colocalized with macrophages and neovessels were detected mainly in the
calcified regions of the leaflets. The number of MCs positively correlated with maximal (r00.73, P<
0.0001) and mean (r00.78, P<0.0001) gradients and maximal aortic jet velocity (r00.68, P00.0005).
An inverse correlation with aortic valve area (r0−0.71, P00.0001) was also observed. Multivariate
regression analysis revealed that MC number and valve thickness were significantly associated with
mean transvalvular gradient (R200.74, P<0.000001) in AS patients. Increased MC number within
human stenotic aortic valves is associated with the severity of AS.
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INTRODUCTION
Aortic valve stenosis (AS) is a common cardiac
valve acquired defect in older subjects. The narrowing of
the valve opening that occurs as a result of calcification
is related to the high pressure gradient across the stenotic
valve [1]. In recent years AS has been perceived as an
active inflammatory process that shares many similari-
ties with atherosclerosis, including subendothelial accu-
mulation of oxidized lipoproteins, calcification [2], and
infiltration of inflammatory cells, in particular T cells,
macrophages [3], and mast cells (MCs) [4]. Upon
activation, MCs are able to synthesize a large number
of proinflammatory and profibrotic mediators, followed
by their slow and sustained secretion [5]. In humans
MCs are classified according to their protease content,
with the tryptase-positive MCs expressing tryptase only
and the tryptase- and chymase-positive MCs expressing
all types of MC proteases, that is, tryptase, chymase, and
MC–carboxypeptidase A [6]. MC proteases have a
variety of roles, inflammatory and anti-inflammatory,
protective and deleterious, in keeping with the increas-
ingly well-appreciated contributions of mast cells in
allergy, innate immunity, and tissue homeostasis [7].
Growing evidence suggests that MCs may be
actively involved in the progression of AS. In stenotic
aortic valves, MC-derived chymase can stimulate angio-
tensin II formation [4]. Increased Ang II production, in
turn, may mediate collagen gene transcription by
stimulating the expression of transforming growth
factor-β (TGF-β) [4]. TGF-β1 was shown to be
characteristically accumulated in MCs [4] as well as in
the extracellular matrix and mineral deposits in calcified
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aortic valve cusps [2]. Studies with transgenic mice have
indicated that increased mast cell density with a resultant
increase in TGF-β-mediated profibrotic signaling between
cardiac mast cells and resident cardiac fibroblasts is
required for the development of myocardial fibrosis [8].
MCs have also been identified as a major source of
cathepsin G, an enzyme with lytic actions on elastic
fibers, involved in TGF-β pathway activation [9].
Furthermore, MCs located in close proximity to blood
vessels together with myofibroblasts are implicated in
valve neoangiogenesis [10]. These findings suggest that
activated and degranulated MCs present within fibrotic
lesions of the aortic valves may participate in the
induction of fibrosis and calcification with ensuing valve
stiffening [4, 9]. However, to the best of our knowledge,
there have been no reports showing associations be-
tween MCs within stenotic aortic valves and severity of
AS. Therefore, the aim of the current study was to test
the hypothesis that, as in advanced atherosclerotic
plaques [11], MCs may contribute to the severity of AS.
METHODS
Patients
A total of 43 consecutive patients (19 men and 24
women) undergoing isolated elective aortic valve re-
placement for moderate to severe AS were recruited.
Only patients with acquired aortic stenosis were includ-
ed in the study. The exclusion criteria were: a bicuspid
valve, low-output low-gradient aortic stenosis and an
ejection fraction <40 %, diabetes mellitus, acute infec-
tion, Valsalva sinus aneurysm or rheumatic AS, angio-
graphically documented coronary artery stenosis >20 %
diameter, carotid artery stenosis, known cancer, autoim-
mune disorders, endocarditis, previous cardiac surgery, a
history of myocardial infarction, stroke, venous throm-
boembolism, or bleeding. Patients who required addi-
tional surgical intervention or had other heart defects
were ineligible.
Information on the presence or absence of cardiovas-
cular risk factors, including arterial hypertension, hyperlip-
idemia, smoking, diabetes mellitus, and use of statins,
angiotensin-converting enzyme inhibitors (ACEIs), β-
blockers, and acetylsalicylic acid, was obtained before
surgery. Smoking was defined as the use of one or more
cigarettes per day. Patients receiving insulin or oral
hypoglycemic agents, or having at least two random fasting
glucose levels of >7 mmol/l, were classified as having
diabetes mellitus. Arterial hypertension was diagnosed
based on a history of hypertension (blood pressure >140/
90 mmHg) or preadmission antihypertensive treatment.
Hyperlipidemia was diagnosed based on medical records,
statin therapy, or total cholesterol of 5.2 mmol/l or more.
Renal failure was diagnosed based on having at least two
random fasting creatinine levels of >110 μmol/l for males
and >80 μmol/l for females. Five aortic valves from age-
matched healthy subjects, obtained at autopsy, without
morphological AS or other valvular disorders, served as
negative controls.
Patients gave their informed written consent, and
the study was approved by the University Bioethical
Committee.
Echocardiography
Transthoracic echocardiography was performed in
each patient using a MargotMac 5000 ultrasound
machine prior to surgery using conventional techniques
in accordance with the European Society of Cardiology
guidelines. The aortic valve area (AVA) was calculated
using the standard continuity equation [12]. The trans-
valvular gradient was measured by Doppler echocardi-
ography using the modified Bernoulli equation [12].
Laboratory Tests
Fasting venous blood was drawn from patients 24 h
before surgery between 7 and 9 AM. Citrated blood
samples (9:1 of 0.106 M sodium citrate) were centri-
fuged at 3,000 rpm at 20 °C for 10 min and stored in
aliquots at −80 °C until analysis. Lipid profile, glucose,
and creatinine were assayed by routine laboratory
techniques. High-sensitivity C-reactive protein (CRP)
was determined using immunoturbidimetry (Roche
Diagnostics GmbH, Mannheim, Germany).
Analysis of Aortic Valves
Diseased aortic valves were collected during sur-
gery for valve replacement. After decalcification, per-
formed as previously described [13], valves were
embedded in Tissue Tec-OCT compound (Sakura,
Torrance, CA, USA) for tissue cryopreservation and
cryosectioned (8–10-μm-thick sections) onto SuperFrost
slides (Menzel-Glaser, Germany) by a Leica Jung CM
3000 cryostat. Sections were taken transversely from the
middle of the leaflet and from commissural areas. Slides
were stored at −20 °C until morphological analysis and
immunostaining. To ascertain the morphology of the
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leaflets, one hematoxylin–eosin section, taken from
sections obtained from each leaflet, was observed using
optical microscopy before the other cryosections were
subjected to the immuno- and morphometric evaluation.
The valve thickness was measured in the lesion
area, defined as total thickness of the leaflets [13].
Immunostaining Analysis
Undecalcified serial sections were stained with von
Kossa's stain (Sigma, St. Louis, MO, USA) to localize
ionized calcium deposits. Immunofluorescence and
immunohistochemistry were performed on adjacent
sections of aortic valves as described before [13].
Briefly, after endogenous peroxidase activity quenching
and blocking of unspecific background, primary ade-
quate monoclonal antibodies were applied overnight at
4 °C against human mast cell anti-tryptase (Dako,
Glostrup, Denmark) and anti-chymase (Serotec, Hanar,
Germany), human macrophage (anti-CD68 antigen,
Santa Cruz Biotechnology Inc., CA, USA), or a neo-
vascularization marker, tyrosine kinase receptor Tie-2
(Abcam, Cambridge, UK).
Primary antibodies were followed by the
corresponding secondary antibodies conjugated with
fluorochrome (Santa Cruz Biotechnology Inc., CA,
USA) or by the avidin–biotin complex immunoperox-
idase according to the manufacturer's instructions (Santa
Cruz Biotechnology Inc., CA, USA). Diaminobenzidine
was used as the chromogen. A negative control (without
primary antibody incubation) was included routinely.
Sections were viewed in fluorescence or light micro-
scope (both Zeiss, Berlin, Germany). Photomicrographs
were taken using a Canon A640 camera and analyzed
using the image analysis software CellProfiler Analyst.
The exact numbers of tryptase-positive and chymase-
positive MCs in the calcified region of each section were
counted by light microscopy as described previously
[14]. Tie-2 expression was analyzed semiquantitatively
according to the following scoring system: 0, absence; 1,
isolated neovessels (<10 % of the total leaflet area), and
2, abundant neovessels (>10 % of the total leaflet area).
Valvular Calcification
Valvular calcification was analyzed semiquantita-
tively according to the following scoring system: 1,
isolated calcium deposits; 2, calcification occupying less
than 20 % of the total leaflet area, and 3, abundant
calcium deposits occupying more than 20 % of the total
leaflet area.
Statistical Analysis
Values are expressed as mean (SD) or median
(interquartile range) or otherwise stated. The Kolmo-
gorov–Smirnov test was used to assess conformity with
a normal distribution. Pairwise comparisons were made
using Tukey's test for continuous variables and the chi2
test for proportions. The Mann–Whitney U test was used
to compare non-normally distributed variables between
two groups. Spearman's correlation coefficient was
calculated to evaluate associations between variables. A
multivariate stepwise linear regression analysis was
performed to evaluate the potential contribution of
clinical and demographical variables to mean
transvalvular gradient. A value of P<0.05 was
considered statistically significant.
RESULTS
Laboratory Parameters
The demographic, clinical, and echocardiographic
parameters in the AS patients are summarized in Table 1.
Valvular stenosis was moderate to severe with maximal
transvalvular gradient of 96.2±25.87 mmHg and mean
gradient of 62.11±24.47 mmHg. Left ventricular ejec-
tion fraction was 55.8±12.4 %. Plasma fibrinogen and
CRP levels were 3.78±0.8 g/l and 6.2 (1.22–21.2)mg/l,
respectively.
Aortic Valve Tissue Analysis
Total valve leaflet thickness was 1.36 (0.98–2.94)
mm. Focal areas of subendothelial thickening compris-
ing roughly two thirds of the aortic side of the leaflet
were seen in all AS valves as compared with the control
group, in which no lesions were observed. Large
amounts of calcium deposits in the fibrosa and the
subendothelial layer at the aortic side of the leaflets were
detected in all AS valves. Any increase in fibrosis and
lipid insudation was observed in negative control valves.
Immunohistochemistry and Immunofluorescence
AS valves were characterized by an increased
number of tryptase- and chymase-positive MCs, com-
pared with the control valves (6.9 [2.3–18.9]/mm2 vs.
0.7 [0–2.2]/mm2, P00.0001, and 3.2 [2.1–9.4]/mm2 vs.
0.3 [0–1.9]/mm2, P00.002, respectively) (Fig. 1). MCs
were noted in 100 % of the stenotic valves. The
accumulation of MCs was evident in the subendothelial
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region as well as throughout the leaflets predominantly
in the calcified areas (Fig. 2).
The regions of the aortic valve showing abundant
calcification had increased MC numbers compared with
those with isolated calcium deposits (8.82±3.31/mm2 vs.
4.82±0.94/mm2, P00.0003). Moreover, there was a
significant difference in the degree of calcification in
patients with mean transvalvular gradient more than
50 mmHg compared to those with a gradient less than or
equal to 50 mmHg (2.68±0.15 vs. 2.25±0.16/mm2, P0
0.05). Larger Tie-2-positive areas were associated with a
higher number of MCs compared to those without Tie-2
expression (8.84±2.02/mm2 vs. 5.06±1.14/mm2, P0
0.0003). Any correlation between MC numbers and
valve thickness was observed.
MCs colocalized with macrophages mainly in the
lesion area of the stenotic aortic valves (Fig. 2c). There
was a strong positive correlation between the number of
MCs and macrophages (r00.66, P00.0001). Quartile
analysis of plasma CRP levels showed that AS patients
in the highest quartile (>3.90 mg/l, n011) had elevated
numbers of MC compared to those in the lowest
(<1.20 mg/l, n011) (8.62±3.41/mm2 vs. 6.13±1.83/
mm2, P00.03).
The number of MCs was positively correlated with
maximal (r00.73, P<0.0001) and mean (r00.78, P<
0.0001) gradients and maximal aortic jet velocity (r0
0.68, P00.0005), while an inverse correlation of the
number of MCs with AVA (r0−0.71, P<0.0001) was
observed (Fig. 3). Patients with severe AS with a mean
gradient of >50 mmHg had higher MC numbers than
those with mean gradient ≤50 mmHg (9.64±0.51 vs.
5.10±0.53/mm2, P<0.0001) (Fig. 4).
There were no associations between demographic
variables or cardiovascular risk factors and valvular MC
numbers in AS patients (data not shown). A multivariate
stepwise linear regression analysis identified the MC
numbers and valve thickness as the independent pre-
dictors of mean transvalvular gradient (R200.74, P<
0.000001) in AS patients (Table 2).
DISCUSSION
We demonstrate that increased MC numbers within
human stenotic aortic valves, mainly in calcified areas,
are associated with the severity of AS. This study is the
first to show that the higher the number of MCs, the
more severe AS is in subjects without evidence of
atherosclerotic vascular disease. The presence of numer-
ous degranulated MCs and their local accumulation has
been described within human aortic valves by Helske et
al. [4]. MCs can also be detected from the earliest to the
most advanced stages of atherosclerosis [15], and their
number increased linearly with increasing severity of the
disease [16]. During atherosclerotic lesion progression, it
Table 1. Patients Characteristics
AS (n043)
Demographic data
Male, n (%) 19 (44)
Age, years 64.2±5.9
Body mass index (kg/m2) 28.3±5.7
Risk factors
Hypertension, n (%) 23 (53)
Hypercholesterolemia, n (%) 14 (33)
Currently smoking, n (%) 3 (7)
Medication
Beta-blockers, n (%) 12 (30)
Acetylsalicylic acid, n (%) 23 (53)
ACEI, n (%) 12 (30)
Statins, n (%) 11 (26)
Echocardiography
Maximum gradient, mmHg 96.2±25.87
Mean gradient, mmHg 62.11±24.47
LVEF, % 55.82±12.42
Calcified valves, n (%) 43 (100)
Aortic bulb width, cm 2.68±1.25 (n025)
Ascending aortic width, cm 3.63±0.97
Vmax 4.82±9.72 (n021)
AVA, cm2 0.72±0.26 (n027)
Values are given as mean (SD) or number (percentage)
ACEI angiotensin-converting enzyme inhibitors, AVA aortic valve area,
LVEF left ventricular ejection fraction, V max maximum aortic jet
velocity
Fig. 1. The number of tryptase- (a) and chymase-containing (b) MCs in
normal (control) and stenotic (AS) aortic valves. Lines indicate means.
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has been shown that MCs accumulate in the rupture-
prone shoulder region of human atheromas [11] and in
the perivascular tissue (adventitia) reaching even 104±
15 cells/mm2 in the most advanced lesions [16]. Our
findings indicate that in AS patients showing no
evidence of coronary or carotid stenosis, significant
amounts of MCs, though lower than in unstable plaques,
are present within their valves in association with
transvalvular gradients and AVA.
It has been demonstrated that accumulation of MCs
within inflamed tissue could occur by local proliferation
of resident MCs, increased recruitment of MC precursors
from the circulation, or migration of mature MCs from
adjacent tissues. In our study, MCs were found in
calcified areas and in the subendothelial layer on the
aortic side of the stenotic leaflets, which is consistent
with previous findings [4, 9]. The aortic side of the
leaflets is an area of flow perturbations and low shear
stress, so predisposing to endothelial injury and subse-
quent infiltration of inflammatory cells and plasma
lipoproteins [3]. We may speculate that the damaged
side of the leaflets may be the region of MC migration
from circulation to the inflammatory lesion. Undoubted-
ly, macrophages accumulating in large numbers within
Fig. 2. Representative micrographs of MC staining within stenotic aortic valves using immunofluorescence (a, c; green) and immunohistochemistry
(b, brown). Double-labeled immunostaining (c) shows that MCs (green) are present in the vicinity of macrophages (red). Nuclei were counterstained
with DAPI (blue). Original magnification, ×40; insert, ×100. *aortic side of the leaflet.
Fig. 3. Correlation between transvalvular maximal gradient (a), mean gradient (b), maximum aortic jet velocity (Vmax, c), aortic valve area (AVA, d),
and MC expression.
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stenotic aortic valves [3] are key players in the
pathogenesis of AS. They secrete a variety of factors
that activate valve myofibroblasts and trigger their
osteoblastic transdifferentiation as well as promote
monocyte migration into developing aortic valve steno-
sis [17]. MCs may be a secondary phenomenon to
degeneration and calcification of aortic leaflets. Our
immunohistochemical analysis revealed colocalization
of MCs with macrophages around the calcified areas,
suggesting their close cooperation. Moreover, similarly
to atherosclerotic plaques, activated MCs may contribute
to macrophage accumulation within valvular lesions
either by their direct recruitment [18] or by inducing
the secretion of monocyte chemoattractant protein-1
from fibroblasts [19].
We have also found that the MC numbers were
associated with the expression of Tie-2 marker suggest-
ing that neovascularization enhances infiltration of MCs
and/or vice versa. It has been reported that in AS valves,
MCs actively contribute to valve neoangiogenesis as
they stored and secreted proangiogenic vascular endo-
thelial growth factor [10]. The presence of neovessels
may facilitate the influx of substances implicated in
aortic valve degeneration and increase macrophage
recruitment [10].
Interestingly, during persistent inflammation and
tissue remodeling, MC populations can undergo signif-
icant changes, not only in the number but also in the
content of stored mediators, in response to microenvir-
onmental changes [20]. In atherosclerotic lesions acti-
vated MCs promote atherosclerotic plaque progression
and destabilization by increasing the risk of intraplaque
hemorrhage, intimal leukocyte influx, and macrophage
apoptosis [21]. As in atherosclerosis, the final result is
plaque development and plaque instability whereas in
AS, severe calcification of the aortic valve and fibro-
calcific thickening is the end stage of the disease. We
have confirmed that the degree of valvular calcification
in AS valves corresponds with an increased number of
MCs. Moreover, in our study severe leaflet calcification
was associated with higher transvalvular gradient.
It is known that MCs participate in the pathogenesis
of aortic valve calcification by secreting the proteases
tryptase, chymase, and cathepsin G, which may directly
degrade the extracellular matrix of valves [4, 9]. Mast
cell-derived chymase, in addition to forming Ang II,
may contribute to valvular fibrosis by promoting MC
migration and degranulation and by generating an active
form of TGF-β [5]. Within aortic valves, TGF-β
enhances collagen synthesis and may contribute to the
progression of aortic stenosis by initiating the apoptosis-
related calcification of aortic valve interstitial cells [2].
The presence of activated MCs in the inflamed stenotic
valves and their contribution to severe leaflet calcifica-
tion and mineralization may lead to increased trans-
valvular gradients and decreased aortic valve area. Our
findings confirm this hypothesis as we observed strong
positive associations between MC numbers and maximal
and mean gradient as well as maximum aortic jet
Fig. 4. Associations between MC expression and mean transvalvular gradient in AS patients with gradient more than 50 mmHg or less than or equal
to 50 mmHg. Values are given as mean±standard deviation.
Table 2. Summary of the Additive Regression Models (Stepwise
Method): Predictor Contribution to the Mean Transvalvular Gradient in
AS Patients
R200.74, P<0.00001 β coefficient SE P value
MC (cells/mm2) 6.05 0.59 <0.00001
Valve thickness 8.36 3.34 0.02
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velocity. Moreover, valvular MC numbers were signif-
icantly increased in patients with severe AS compared to
those with moderate AS. Importantly, we have indicated
that MC numbers are the best predictors of mean
transvalvular gradient which supports the hypothesis
that the presence of MCs contributes to the progression
of AS.
In our study increased MC numbers was also
associated with elevated serum CRP levels which may
reflect chronic inflammation in diseased aortic valves
and activity of inflammatory cells. Indeed it was shown
by others that ongoing inflammation in the valve leaflets
is associated with elevated serum CRP level [22]. One
might speculate that CRP influences MC number
through complement activation which occurs in the
stenotic valve leaflets [23]. C3a and C5a have been
shown to participate in MC recruitment [24] and are able
to induce their activation. On the other hand it is also
possible that CRP itself may participate in valve
calcification. In an in vitro simulating model, rising
CRP levels progressively increased the rate of aortic
wall calcification [25].
The study has several limitations. First, the
number of the patients enrolled in this study was
small. Secondly, our findings likely cannot be
extrapolated on subjects with mild AS or with aortic
sclerosis as we focused on the valves obtained from
patients with severe AS scheduled for surgery. Third,
we did not perform double staining to distinguish
chymase- and tryptase-positive cells from tryptase-
positive cells to determine which subtypes more
strongly determine AS severity.
In summary, we showed that MCs are associated
with the severity of AS in humans, suggesting an active
involvement of these cells in the progression of this
disease. Increased MC numbers present in human AS
valves enhance valvular inflammation associated with
aortic valve calcification and neovascularization, restrict-
ed leaflet motion, and AS severity. It is tempting to
hypothesize that inhibition of MC activation and
degranulation within stenotic aortic valves may be an
important target in the development of therapeutic
approaches to prevent progression of AS. This issue
merits further investigation.
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